# The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

> **NCT05904015** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 80 (estimated)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
- **DRUG:** Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)

## Key facts

- **NCT ID:** NCT05904015
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904015, "The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05904015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*